FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2065984477> ?p ?o ?g. }

• W2065984477 endingPage "276" @default.
• W2065984477 startingPage "268" @default.
• W2065984477 abstract "Insulin receptors (IRs) are highly expressed in the central nervous system (CNS) and play an important role in normal brain functions, such as learning and memory. Due to the increasing rate of obesity in western societies and overall high fat diets, the incidents of neuronal insulin resistance is also on the rise, but the underlying mechanism is still poorly characterized. We found that cholesterol treatment produces robust insulin signaling resistance that is characterized by the marked reduction in insulin-stimulated tyrosine phosphorylation of the IR and its downstream targets insulin receptor substrate 1 (IRS1) and 2 (IRS2). Surface expression of IRs was also decreased and was correlated with an increase in facilitated receptor endocytosis. Membrane fractionation showed that after cholesterol treatment, the proportion of IRs localized in the lipid raft increased and correspondingly there was a reduction of IRs in the non-raft membrane. Interestingly, we found that IRs in the lipid rafts, unlike their counterparts in the non-raft membrane domain, were essentially unresponsive to insulin stimulation and that a high level of tyrosine phosphatase activity was associated with these raft fractions. Our results suggest that the lipid raft microdomain of the neuronal plasma membrane has a strong influence on IR signaling, and that incorporation of high levels of cholesterol may reduce IR signaling by increasing their representation in lipid rafts. The trapping of the IR in the lipid raft domain may result in its inactivation and promote its endocytosis: effects that could contribute to neuronal insulin resistance in obesity." @default.
• W2065984477 created "2016-06-24" @default.
• W2065984477 creator A5005955897 @default.
• W2065984477 creator A5027351735 @default.
• W2065984477 creator A5046836758 @default.
• W2065984477 creator A5047446019 @default.
• W2065984477 creator A5047476496 @default.
• W2065984477 creator A5074621440 @default.
• W2065984477 date "2009-09-01" @default.
• W2065984477 modified "2023-09-24" @default.
• W2065984477 title "Mechanisms involved in cholesterol-induced neuronal insulin resistance" @default.
• W2065984477 cites W1491692384 @default.
• W2065984477 cites W1520589624 @default.
• W2065984477 cites W1543788907 @default.
• W2065984477 cites W1573704377 @default.
• W2065984477 cites W1627446849 @default.
• W2065984477 cites W1964562779 @default.
• W2065984477 cites W1967239279 @default.
• W2065984477 cites W1968659767 @default.
• W2065984477 cites W1969918683 @default.
• W2065984477 cites W1971462812 @default.
• W2065984477 cites W1974642006 @default.
• W2065984477 cites W1975494637 @default.
• W2065984477 cites W1985929283 @default.
• W2065984477 cites W1991854031 @default.
• W2065984477 cites W1992431456 @default.
• W2065984477 cites W1998321044 @default.
• W2065984477 cites W2000351678 @default.
• W2065984477 cites W2005192572 @default.
• W2065984477 cites W2006851823 @default.
• W2065984477 cites W2009173763 @default.
• W2065984477 cites W2011430246 @default.
• W2065984477 cites W2011649140 @default.
• W2065984477 cites W2012785062 @default.
• W2065984477 cites W2017088069 @default.
• W2065984477 cites W2020258403 @default.
• W2065984477 cites W2020514995 @default.
• W2065984477 cites W2022669791 @default.
• W2065984477 cites W2024204570 @default.
• W2065984477 cites W2024235773 @default.
• W2065984477 cites W2027108824 @default.
• W2065984477 cites W2028149754 @default.
• W2065984477 cites W2035825704 @default.
• W2065984477 cites W2037226098 @default.
• W2065984477 cites W2040945595 @default.
• W2065984477 cites W2041205811 @default.
• W2065984477 cites W2045522606 @default.
• W2065984477 cites W2047493091 @default.
• W2065984477 cites W2051005741 @default.
• W2065984477 cites W2051927904 @default.
• W2065984477 cites W2056030232 @default.
• W2065984477 cites W2058930537 @default.
• W2065984477 cites W2060669063 @default.
• W2065984477 cites W2061489988 @default.
• W2065984477 cites W2063872972 @default.
• W2065984477 cites W2064581339 @default.
• W2065984477 cites W2064707735 @default.
• W2065984477 cites W2071533902 @default.
• W2065984477 cites W2072500349 @default.
• W2065984477 cites W2075740571 @default.
• W2065984477 cites W2077033935 @default.
• W2065984477 cites W2082058995 @default.
• W2065984477 cites W2084761782 @default.
• W2065984477 cites W2089629277 @default.
• W2065984477 cites W2089643815 @default.
• W2065984477 cites W2092271417 @default.
• W2065984477 cites W2093052372 @default.
• W2065984477 cites W2096439143 @default.
• W2065984477 cites W2097157695 @default.
• W2065984477 cites W2105484754 @default.
• W2065984477 cites W2106492868 @default.
• W2065984477 cites W2108899090 @default.
• W2065984477 cites W2114911095 @default.
• W2065984477 cites W2116403898 @default.
• W2065984477 cites W2120282127 @default.
• W2065984477 cites W2121936687 @default.
• W2065984477 cites W2126317966 @default.
• W2065984477 cites W2126490785 @default.
• W2065984477 cites W2128738365 @default.
• W2065984477 cites W2130850001 @default.
• W2065984477 cites W2134539481 @default.
• W2065984477 cites W2135447862 @default.
• W2065984477 cites W2135896596 @default.
• W2065984477 cites W2141277427 @default.
• W2065984477 cites W2143213067 @default.
• W2065984477 cites W2144486959 @default.
• W2065984477 cites W2147403614 @default.
• W2065984477 cites W2159615155 @default.
• W2065984477 cites W2159988116 @default.
• W2065984477 cites W2162030013 @default.
• W2065984477 cites W2163507164 @default.
• W2065984477 cites W2797870555 @default.
• W2065984477 cites W4230882040 @default.
• W2065984477 cites W4239111638 @default.
• W2065984477 cites W4240737306 @default.
• W2065984477 cites W4251813527 @default.
• W2065984477 cites W4254261652 @default.
• W2065984477 doi "https://doi.org/10.1016/j.neuropharm.2009.05.013" @default.

• next